Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage

Kidney and Blood Pressure Research

Volumn 30, Issue 4, 2007, Pages 224-233

  Benz, Kerstin ^a   Orth, Stephan R ^b   Simonaviciene, Aurelia ^c   Linz, Wolfgang ^d   Schindler, Ursula ^d   Rütten, Hartmut ^d   Amann, Kerstin ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c KfH Weiden   (Germany)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Chronic renal failure; Guanylyl cyclase activator; HMR1766; Nitric oxide; Progression

Indexed keywords

ALBUMIN; GUANYLATE CYCLASE ACTIVATOR; HEME; HMR 1766; RAMIPRIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOSE RESPONSE; GLOMERULOSCLEROSIS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; MALE; NONHUMAN; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; STATISTICAL SIGNIFICANCE; URINARY EXCRETION;

ANIMALS; ANTHRANILIC ACIDS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GUANYLATE CYCLASE; HEME; KIDNEY FAILURE, CHRONIC; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONAMIDES; TIME;

EID: 34447512957     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104091     Document Type: Article

References (34)

1. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, Ritz E: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-2461.
2. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
3. Kaysen GA, Eiserich JP: The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004;15:538-548.
4. Boon EM, Huang SH, Marletta MA: A molecular basis for NO selectivity in soluble guanylate cyclase. Nat Chem Biol 2005;1:53-59.
5. Schindler U, Strobel H, Schonafinger K, Linz W, Lohn M, Martorana PA, Rutten H, Schindler PW, Busch AE, Sohn M, Topfer A, Pistorius A, Jannek C, Mulsch A: Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol Pharmacol 2006;69:1260-1268.
6. Gladwin MT: Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. J Clin Invest 2006;116:2330-2332.
7. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H SA, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Muller-Esterl W, Schmidt HH: Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006;116:2552-2561.
8. Liu YC, Wu SN: BAY 41-2272, a potent activator of soluble guanylyl cyclase, stimulates calcium elevation and calcium-activated potassium current in pituitary GH cells. Clin Exp Pharmacol Physiol 2005;32:1078-1087.
9. Schindler U KM, Linz W, Rütten H, Schäfer S, Strobel H, Schäfer A, Bauersachs J, Wassmann S, van Eickels M: Role of activators of ferric sGC in cardiovascular disease. BMP Pharmacology 2005;5(suppl I):S19.
10. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT: Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006;113:286-295.
11. Deruelle P, Balasubramaniam V, Kunig AM, Seedorf GJ, Markham NE, Abman SH: BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol Neonate 2006;90:135-144.
12. Theilig F, Bostanjoglo M, Pavenstadt H, Grupp C, Holland G, Slosarek I, Gressner AM, Russwurm M, Koesling D, Bachmann S: Cellular distribution and function of soluble guanylyl cyclase in rat kidney and liver. J Am Soc Nephrol 2001;12:2209-2220.
13. Hohenstein B, Daniel C, Wagner A, Stasch JP, Hugo C: Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis. Am J Physiol 2005;288:F685-F693.
14. Peters H, Wang Y, Loof T, Martini S, Kron S, Kramer S, Neumayer HH: Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis. Kidney Int 2004;66:2224-2236.
15. Wang Y, Kramer S, Loof T, Martini S, Kron S, Kawachi H, Shimizu F, Neumayer HH, Peters H: Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. Kidney Int 2005;68:47-61.
16. Kalk P, Godes M, Relle K, Rothkegel C, Hucke A, Stasch JP, Hocher B: NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br J Pharmacol 2006;148:853-859.
17. Becker RH, Baldes L, Furst U, Schulze KJ: Sustained diurnal blood pressure reduction in SHR with ramipril assessed by telemetric monitoring. Clin Exp Hypertens 1997;19:1233-1246.
18. Fruhwald FM, Fahrleitner A, Watzinger N, Fruhwald S, Dobnig H, Schumacher M, Maier R, Zweiker R, Klein WW: Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy. Eur Heart J 1999;20:1415-1423.
19. Franz M, Woloszczuk W, Horl WH: N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int 2000;58:374-383.
20. Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, Fujino M, Ajisaka R, Goto K, Masaki T: Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 1989;ii:53-54.
21. Kraus T, Mehrabi A, Klar E, Mathias D, Arnold J, Otto G, Herfarth C: Peri and postoperative plasma kinetics of big endothelin and endothelin 1/2 after liver transplantation. Transplant Proc 1992;24:2569-2571.
22. Linz W, Wiemer G, Schmidts HL, Ulmer W, Ruppert D, Scholkens BA: ACE inhibition decreases postoperative mortality in rats with left ventricular hypertrophy and myocardial infarction. Clin Exp Hypertens 1996;18:691-712.
23. Amann K, Nichols C, Tornig J, Schwarz U, Zeier M, Mall G, Ritz E: Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996;11:1003-1011.
24. Veniant M, Heudes D, Clozel JP, Bruneval P, Menard J: Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. Kidney Int 1994;46:421-429.
25. Amann K, Ritz E: The heart in renal failure: morphological changes of the myocardium: new insights. J Clin Basic Cardiol 2001;4:109-113.
26. Amann K, Rychlik I, Miltenberger-Milteny G, Ritz E: Left ventricular hypertrophy in renal failure. Kidney Int Suppl 1998;68:S78-S85.
27. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, Zapol WM: Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 2004;110:2253-2259.
28. Zanfolin M, Faro R, Araujo EG, Guaraldo AM, Antunes E, De Nucci G: Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J Cardiovasc Pharmacol 2006;47:391-395.
29. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC Jr: Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 2003;107:686-689.
30. Brioni JD, Nakane M, Hsieh GC, Moreland RB, Kolasa T, Sullivan JP: Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res 2002;14:8-14.
31. Wang Y, Kramer S, Loof T, Martini S, Kron S, Kawachi H, Shimizu F, Neumayer HH, Peters H: Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. Am J Physiol 2006;290:F167-F176.
32. Sindhu RK, Ehdaie A, Vaziri ND, Roberts CK: Effects of chronic renal failure on caveolin-1, guanylate cyclase and AKT protein expression. Biochim Biophys Acta 2004;1690:231-237.
33. Oberwittler H, Hirschfeld-Warneken A, Wesch R, Willerich H, Teichert L, Lehr KH, Ding R, Haefeli WE, Mikus G: Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. J Clin Pharmacol 2007;47:70-77.
34. Namnum P, Insogna K, Baggish D, Hayslett JP: Evidence for bidirectional net movement of creatinine in the rat kidney. Am J Physiol 1983;244:F719-F723.